Moleculin Biotech, Inc. (0K2H.L)

4.4300 +0.0800 (+1.84%) As of 02:32PM BST. Market open.

Moleculin Biotech, Inc.

5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
(713) 300-5160
https://moleculin.com

Sector(s): 
Industry: 
Full-time employees: 18

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Walter V. Klemp	Founder, Chairman, President & CEO	894.54k	N/A	1960
Mr. Jonathan P. Foster CPA	Executive VP & CFO	611.17k	N/A	1964
Dr. Donald H. Picker Ph.D.	Chief Scientific Officer	486.44k	N/A	1946
Dr. Waldemar Priebe Ph.D.	Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Robert C. Shepard FACP, M.D.	Chief Medical Officer of Annamycin	N/A	N/A	1952
Dr. John Paul Waymack M.D., Sc.D.	Senior Chief Medical Officer	N/A	N/A	1952
Dr. Sandra L. Silberman M.D., Ph.D.	Chief Medical Officer of New Products	N/A	N/A	1956
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.	European Chief Medical Officer	N/A	N/A	N/A
Ms. Jacqueline Northcut	Consultant	51.11k	N/A	1962
Mr. Louis Ploth Jr.	Independent Advisor	118.49k	N/A	1954

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Corporate governance

Moleculin Biotech, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.